Covid phenomena treatment
![covid phenomena treatment covid phenomena treatment](https://mma.prnewswire.com/media/1225584/X_Ray.jpg)
The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml −1, 85.9% ( n = 510) of whom were receiving dexamethasone.
Covid phenomena treatment Activator#
Nature Medicine volume 27, pages 1752–1760 ( 2021) Cite this articleĮarly increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial